News Archives - Page 2 of 3

May 12 2011

原文链接中新网5月13日电据美国《世界日报》报道，美国新泽西州生化遗传学者麻建杰发现MG53蛋白在细胞膜修复中的作用，并在多家专业生化期刊中发表这项基因蛋白质的修复功能，引起生医界重视。麻建杰已自行成立TRI-Medicine药厂，积极开发新药，该项目已获新泽西州科技协会、美国国家健康研究所和私人企业等250万元基金赞助。今年47岁的麻建杰来自河南洛阳，毕业于武汉大学物理系，1984年...

TRIM-edicine received an NIH-SBIR grant to develop pre-clinical studies with MG53.

Dr. Jianjie Ma’s group at The Ohio State University published a paper “Treatment of acute lung injury by targeting MGG53-mediated cell membrane repair” in Nature Communications

TRIM-edicine, Inc was awarded a SMARTT (Science Moving towArds Research Translation and Therapy ) grant from NHLBI for supporting of CMC development.

TRIM-edicine was awarded a SBIR I grant entitled “Targeting ATAP-mediated apoptosis in treatment of prostate cancer” by NIH-NCI.

TRIM-edicine held a Pre-IND meeting with FDA on the use of rhMG53 as therapeutics for treatment of unmet medical needs.

TRIM-edicine was awarded US patent on serum MG53 as a diagnostic marker for tissue injury.

TRIM-edicine was awarded $1.5 M from NIH in support of a SBIR phase II project entitled “Protein Therapeutics in Muscular Dystrophy”.

TRIM-edicine publishes its findings on MG53, cell membrane repair, and muscular dystrophy on the cover page of Science Translational Medicine.

中新网：“美华裔研究蛋白修复获大突破成立药厂开发新药“

Dr. Jianjie Ma, Founder of TRIM-edicine, was featured in The Star Ledger: “In UMDNJ lab, discovery could boost body’s resilence”

Archive for Category: News